Ograniczanie wyników

Czasopisma help
Autorzy help
Lata help
Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 29

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  opioid
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
Three novel and sensitive enzymatic methods have been developed for the quantification of tramadol in pharmaceutical dosage forms. The proposed methods are based on the reaction of tramadol with 3-methylbenzothiazoline-2-one hydrazone (method A), aniline (method B) and aminoantipyrine in the presence of hydrogen peroxide and horseradish peroxidase to give colored complexes. The colored complexes obtained with 3-methylbenzothiazoline-2-one hydrazone, aniline and aminoantipyrine exhibit absorption maxima at 480 nm, 550 nm and 530 nm, respectively. Regression analysis of Beer’s plots showed good correlation for tramadol in the concentration range (μg/mL) 2-12 for the methods A & B and 4-24 for the method C. The experimental parameters were studied and optimized. The precision and accuracy of the methods were satisfactory. The proposed methods were successfully applied for the quantification of tramadol in 3 brands of commercially available tablet dosage forms. The results were compared satisfactorily with the official method.
In the course of food proteins digestion, mid-molecular weight opioid peptides are generated. Their amine groups might undergo non-enzymatic glycation with glucose which is promoted by pH and temperature. The glycation conditions of morphiceptin (pH 7.8 and temp. 37°C) used in this experiment proved that non-enzymatic glycation of the peptides could take place in the digestive tract. The results obtained herein suggest that glycation decreases the contraction amplitude of isolated rabbit duodenum by 14.1% and changes the immunogenicity of morphiceptin (Tyr-Pro- Phe-Pro-NH2), probably due to a new epitope produced.
Opioids with their large potency in pain relieve have certain undesirable effects like tolerance, dependence and respiratory depression. This is the reason for permanent efforts to create new analgesic compounds devoid of the adverse side effects. PK20 is a novel hybrid of opioidneurotensin peptides synthetized from the C-terminal hexapeptide of neurotensin and endomorphine-2 pharmacophore. This chimeric compound shows clear central and peripheral antinociceptive activity in experimental animals, however nothing is known about the influence of PK20 on respiratory and cardiovascular parameters. The present study was designed to determine the cardiorespiratory effects exerted by an intravenous injection of [Ile9]PK20, analog of PK20 with substitution of tert-leucine by isoleucine9. We also attempted to evaluate whether the effects of the hybrid are mediated by the peripheral neural pathway like vagus nerve. Finally, the contribution of NTS1 neurotensin and opioid receptors in the [Ile9]PK20 cardiorespiratory pattern was tested. Anaesthetized, spontaneously breathing rats were used. Tidal volume was measured at tracheostomy. The timing components of the breathing pattern, arterial blood pressure and heart rate were recorded. Intravenous injection of [Ile9]PK20 at a dose of 100 μg/kg in the intact rats provoked an increase in tidal volume preceded by a prompt shortlived decrease. Immediately after the end of injection brief acceleration of the respiratory rhythm, was ensued by the slowing down of breathing. Changes in respiration were concomitant with a bi-phasic response of the blood pressure: immediate increase was followed by prolonged hypotension. Bilateral midcervical vagotomy eliminated both: tidal volume and respiratory rate responses. Blockade of NTS1 receptors with an intravenous dose of 500 μg/kg of SR 142948, significantly lessened post-[Ile9]PK20 cardiorespiratory effects. Naloxone hydrochloride – antagonist of opioid receptors – failed to block [Ile9]PK20-evoked responses. This study depicts that [Ile9]PK20 acting through neurotensin NTS1 receptors augments the tidal component of the breathing pattern through the vagal pathway. This latter mediates also the respiratory timing response to the drug. Blood pressure effects evoked by an intravenous injection of [Ile9]PK20 occur besides the vagal pathway and might result from activation of the central and peripheral vascular NTS1 receptors. In summary the respiratory effects appeared not to be profound. However, considerable and extended hypotension evoked by [Ile9]PK20 sets the main disadvantage of an analgesic compound.
Opioid peptides are the most effective drugs in controlling pain; their action is elicited by binding to specific membrane receptors. The gastrointestinal tract represents, after the nervous system, the site in which the opioid receptors are expressed at high levels. The opioid agonist morphine has a significant inhibitory effect on intestinal motility, this action is blocked by naloxone an opioid antagonist mainly active at mu and kappa receptors. In this study the presence of mu opioid receptor on rabbit jejunum was investigated by western blot. The effects of beta-endorphin, the endogenous opioid peptide with the highest affinity to the mu opioid receptor and those of naloxone on spontaneous rabbit jejunum contractions were evaluated. Beta-endorphin (10-6M) showed a relaxant effect on jejunum contractility while naloxone showed a dual effect inducing an increase of spontaneous contractility at low concentrations (10-6M, 10-7M, 10-8M) and a decrease when high concentrations (10-3M, 10-4M, 10-5M) were utilized. The obtained results demonstrate that mu opioid receptor is expressed in rabbit jejunum and suggest that this receptor may be involved in mediating the effects of both opioid agonist and antagonist on jejunum contractions.
Background. Ghrelin, a newly discovered hormone is involved mainly in the regulation of body energy homeostasis. It has also been proved that ghrelin affects many other processes including the control of the hypothalamo-pituitary-gonadal axis in vertebrates. Ghrelin interacts also with other peptides and neurotransmitters, which are involved in gonadotropin release, such as endogenous opioid peptides. The aim of the experiment was to compare the effects of ghrelin and naltrexone, an opioid antagonist, on LH secretion by pituitary cells of mature female and male common carp, Cyprinus carpio L. Materials and methods. In the in vitro experiment the time-dependent (10 and 24 h) action of ghrelin (10-7 or 10-6 M) and naltrexone at 10-6 M added alone or in combination on LH secretion by enzymatically dispersed pituitary cells of mature female and male carp (Cyprinus carpio L.) was studied. Results. Ghrelin alone at a dose of 10-6 M stimulated LH secretion after 10 h of female- but not male-derived cell incubations. Ghrelin at 10-7 M had no effect on LH secretion from either female or male cells. Naltrexone alone stimulated LH secretion only after 24 h of female cell culture. In male cells no significant changes in LH secretion in response to naltrexone alone were found after 10 or 24 h incubation period. Combined treatment (ghrelin 10-7 or 10-6 M and naltrexone) stimulated LH secretion in female and male cell incubations at 10 and 24 h: LH levels were significantly higher in comparison to control, to ghrelin alone (in cells of both sexes) and to naltrexone alone (in male cells only). Conclusion. The results suggest that opioids and ghrelin may control LH secretion in carp acting synergistically, probably through the same receptor type. The concept of opioid and ghrelin interaction in the gonadal steroid feedback on LH release is also discussed.
Development of neuropathic pain is accompanied by many changes in immune and glial cells. These changes correspond to activation of immune and glial cells that have been shown to influence the opioid effectiveness and can be modulated by minocycline (a potent inhibitor of microglial activation). In earlier study we have demonstrated that function of opioidergic neurons may be modulated by the immune system. These changes have been shown to be responsible for the efficacy of opioids. The aim of our study was to examine the effect of the minocycline-triggered inhibition of microglia activation on the injury-induced changes and the efficacy of mu and delta opioid receptor ligands in a rat model of neuropathic pain (chronic constriction injury to the sciatic nerve). In cell culture studies, we examined the influence of opioids (morphine, DAMGO, DPDPE, deltorphin II) on activated primary cultured rat microglia by using MTT and/or NO assays. All experiments were performed according to the IASP recommendations and were approved by a local Bioethics Committee. On the spinal cord level the injury to the sciatic nerve induced an up-regulation of IL-1beta, IL-6 expression, CX3CR1 and C1q (marker of microglia, macrophage and leukocyte activation). Chronic administration of minocycline not only diminished neuropathic pain-related behavior and C1q-positive cell activation, but also attenuate the changes in proinflammatory factors like IL1beta, IL-6 and CX3CR1 in the spinal cord and DRG. In in vivo experiments, the analgesic effects of mu-opioid (morphine and DAMGO), but not delta-opioid (DPDPE, deltorphin II) receptor ligands were lower in the rats under neuropathic pain. Moreover, the analgesic effects of morphine and DAMGO, but not DPDPE and deltorphin II were significantly potentiated by minocycline chronic administration. Our in vitro findings that non-stimulated microglia cells respond differently to opioids in comparisons with stimulated cells as measured by MTT and/or NO assays, corresponded well with the results of in vivo studies. Our study underlined that inhibition of microglial activation could differently influence analgesic effects of mu- but not delta-opioid ligands in injury-induced pathologies, which may influence the effect of various opioid drugs used in chronic pain therapy.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.